

Shandell Jason B.  
Form 4  
March 18, 2019

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Shandell Jason B.

2. Issuer Name and Ticker or Trading Symbol  
Amphastar Pharmaceuticals, Inc.  
[AMPH]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/14/2019

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
President and General Counsel

C/O AMPHASTAR  
PHARMACEUTICALS,  
INC., 11570 6TH STREET  
(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

RANCHO  
CUCAMONGA, CA 91730  
(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				(A) or (D)	Price			
Common Stock	03/14/2019		S <sup>(1)</sup>	7,828	D	\$ 20.3742	160,490	D
Common Stock	03/15/2019		M	24,508	A	\$ 10.93	184,998	D
Common Stock	03/15/2019		S	24,508	D	\$ 20.3379	160,490	D
	03/15/2019		A		A	\$ 0	199,540	D

Edgar Filing: Shandell Jason B. - Form 4

Common Stock				39,050 (4)			
Common Stock	03/15/2019	F	5,255 (5)	D	\$ 20.23	194,285	D
Common Stock	03/16/2019	F	8,381 (5)	D	\$ 20.23	185,904	D
Common Stock	03/17/2019	F	9,876 (5)	D	\$ 20.23	176,028	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title
Employee Stock Option (right to buy)	\$ 10.93	03/15/2019		M	24,508	(6) 07/05/2023	Common Stock 24,508
Employee Stock Option (right to buy)	\$ 20.23	03/15/2019		A	86,862	(7) 03/15/2029	Common Stock 86,862

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Shandell Jason B. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	X		President and General Counsel	

## Signatures

/s/ Eva Wen, by power of  
attorney

03/18/2019

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2018.  
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.73 to \$20.64 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$20.12 to \$20.695, inclusive.
- (3) The reported shares are represented by restricted stock units, or RSUs, which vest in four equal annual installments beginning on March 15, 2020.
- (4) The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of RSUs.
- (5) Shares subject to the option are fully vested and immediately exercisable.
- (6) Shares subject to the option vest in four equal annual installments beginning on March 15, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.